Ophthalmic Disease Therapeutics Market Analysis by Age-related Macular Degeneration, Diabetic Macular Edema, & Other Retinal Disorders - Global Forecast to 2030 [Yahoo! Finance]
Viridian Therapeutics, Inc. (VRDN)
Company Research
Source: Yahoo! Finance
Edition): Analysis By Indication (Age-related macular degeneration, Diabetic macular edema, Other retinal disorders), By Therapies, By Distribution Channel, By Region, By Country: Market Insights and Forecast (2020-2030)" report has been added to ResearchAndMarkets.com's offering. The Global Ophthalmic Disease Therapeutics market showcased growth at a CAGR of 3.81% during 2020-2023. The market was valued at USD 21.92 Billion in 2023 which is expected to reach USD 31.67 Billion in 2030. This report provides analysis for the historical period of 2020-2023, the estimates of 2024 and the forecast period of 2025-2030. The report tracks competitive developments, strategies, mergers and acquisitions and new product development. The companies analyzed in the report include Horizon Therapeutics, Viridian Therapeutics, Viatris, Sanofi Novartis, Bayer AG, Teva Pharmaceuticals, F. Hoffmann-La Roche AG, AbbVie, and GSK plc. The global ophthalmic disease therapeutics market is projected to ex
Show less
Read more
Impact Snapshot
Event Time:
VRDN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VRDN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VRDN alerts
High impacting Viridian Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VRDN
News
- Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye DiseaseBusiness Wire
- Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $38.00 price target on the stock.MarketBeat
- Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its "equal weight" rating re-affirmed by analysts at Wells Fargo & Company. They now have a $27.00 price target on the stock.MarketBeat
- Viridian Therapeutics, Inc. (NASDAQ: VRDN) had its price target raised by analysts at Royal Bank of Canada from $44.00 to $47.00. They now have an "outperform" rating on the stock.MarketBeat
VRDN
Earnings
- 11/12/24 - Miss
VRDN
Sec Filings
- 2/14/25 - Form SCHEDULE
- 1/10/25 - Form 8-K
- 12/16/24 - Form 8-K
- VRDN's page on the SEC website